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LETTERS TO THE EDITOR
Troponin T in Acute
Coronary Syndromes:
Mechanisms and Management Issues
We read with great interest the article in JACC by Lindahl et al. (1)
titled “Mechanisms Behind the Prognostic Value of Troponin T in
Unstable Coronary Artery Disease: A FRISC II Substudy.” There
is limited data on the coronary anatomy of patients with acute
coronary syndromes and an elevated troponin level, and this study
provides new data on this important subject.
The investigators reported that the absence of significant
coronary stenosis was more frequent, and three-vessel disease or
left main stenosis was less frequent without, compared with,
detectable troponin T (tnT). We recently reported our findings on
the prevalence of angiographically significant stenosis in patients
with chest pain and an elevated troponin I (tnI) level and normal
levels of creatine kinase (CK) and creatine kinase-MB fraction
(CK-MB) (2). We found that an elevated tnI level with normal
CK and CK-MB levels in patients with chest pain who presented
within 24 h was associated with a high prevalence of angiographi-
cally significant coronary artery stenosis. Patients with an elevated
tnI and normal CK and CK-MB levels had a higher prevalence of
coronary stenosis 50% compared to the group with normal tnI
and CK and CK-MB levels (80% vs. 27%; p  0.001), and a
higher prevalence of coronary stenosis 70% (56% vs. 27%; p 
0.027). Furthermore, those patients with an elevated tnI and
normal CK and CK-MB levels had a lower prevalence of coronary
stenosis 70% compared to the group that had both elevated tnI,
CK and CK-MB levels (56% vs. 84%, p  0.022), but there was
a similar prevalence of coronary stenosis 50% between these two
groups (80% vs. 87%, p  NS).
These angiographic findings highlight the fact that patients
with acute coronary syndromes comprise a heterogeneous popula-
tion with varying degrees of vessel occlusion, and they underscore
several important implications in the treatment of these patients. It
is noteworthy that a good number of patients who presented with
“non-ST elevation myocardial infarction” on the initial 12-lead
electrocardiogram (ECG) subsequently were found to have totally
occluded circumflex arteries. Indeed, in the study by Lindahl et al.
(1), in the group with the highest levels of tnT, occlusion of the left
circumflex artery was more common than in the three other
groups. Presumably, the lack of ST-segment elevation on the
initial 12-lead ECG, despite the left circumflex artery total
occlusion, was due to the relative insensitivity of the standard ECG
in detecting voltage from the posterolateral region of the heart.
Posterior wall infarction may be detected by placing additional
leads in the back of the heart and finding ST-segment elevation in
leads V7 through V9 (3,4).
Furthermore, posterior wall infarction may be inferred by
reciprocal ST-segment depression leads V1 through V3. Thus, in
patients who present with a markedly elevated troponin, but only
nonspecific ST-T wave abnormalities, special attention to ST-
segment depression in the anterior leads, and perhaps the perfor-
mance of additional leads V7 to V9, may be warranted so as to rule
out total occlusion of the artery supplying the posterior wall
of the left ventricle. This practice would be similar to the
performance of a right-sided 12-lead ECG in any patient who
presents with an inferior wall myocardial infraction to rule out
right ventricular infarction (5). Thus, patients with totally occluded
left circumflex arteries would benefit from immediate triage to the
cardiac catheterization laboratory for rapid revascularization. How
many of the patients who presented with left circumflex artery
occlusions also had ECG changes suggestive of posterior wall
injury, specifically ST-segment depression in the anterior precor-
dial leads V1 through V3?
The suggestion that there is an inverted “U”-shaped curve in
the risk of myocardial infarction (MI) is also important data.
We agree with the investigators that this finding supports the
notion that the risk for subsequent MI is dependent on the
amount of remaining jeopardized myocardium. Thus, patients
with the highest level of troponin have a higher risk of death at
one year, but a lower incidence of reinfarction due to the smaller
region of noninfarcted myocardium still at risk. We find the
suggestion in the accompanying editorial by Antman (6) to be
quite provocative. He alluded to the strategy of stratifying the
patients into “low,” “moderate” and “high” troponin levels, and
to use this stratification as a potential basis for subsequent
treatment decisions regarding the use of glycoprotein IIb/IIIa
inhibitors. However, clinical decision making regarding the
absolute cutoff values of markedly elevated troponins, and what
would constitute a “high” level, would be limited by the
differences in the various available assays. Given the marked
heterogeneity in the performance and interpretation of the
cardiac troponin tests, and the variable time measurement
points, could such a scheme be truly implemented in a clinically
relevant fashion whereby the physician would be able to reliably
assess what constitutes a “low” and “high” level in any given
patient?
Finally, the current study found that in men and women with
tnT elevation, 4% and 14%, respectively, had no significant
coronary obstruction. As the investigators (1) pointed out, these
findings may be due to an increase in myocardial oxygen
demand or decrease in oxygen supply unrelated to significant
coronary thrombosis or stenosis. These observations demon-
strate the significant heterogeneity present in the various
underlying etiologies of elevated troponins. It would be of
interest to determine the outcome of patients with elevated
troponins, but without appreciable coronary obstruction or
thrombosis, as these patients would presumably have a lower
event rate compared to the other groups with visible stenosis or
thrombus. Were the investigators able to compare the outcomes
of patients with elevated troponins but relatively “normal”
coronary arteries, and what was the mean elevation of tnT in
this group of patients? Although small in number, these
patients would constitute an important subset of patients who
present with acute coronary syndromes. If the outcomes in this
group of patients with elevated troponins but relatively normal
coronary arteries differed significantly from the rest of the
subjects, then it would support the notion that troponin
elevations are, in and of itself, not equivalent, and that it is not
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merely the troponin elevation, but rather the etiology behind
the elevation, that makes the most difference clinically.
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REPLY
We do appreciate the valuable comments from Drs. Almeda and
Calvin regarding our article (1) and are happy to provide, as a
response to their questions, some further data from the FRISC II
study. Drs. Almeda and Calvin wonder how often electrocardio-
gram (ECG) changes suggestive of posterior wall injury (i.e.,
ST-segment depression in the anterior precordial leads) were
present on admission in patients with occlusion of the left
circumflex artery as the culprit lesion. Unfortunately, the database
did not contain information about ST-segment depression in each
of the 12 individual leads, but only whether ST-segment depres-
sion was present in anterior, lateral or inferior leads. However, in
patients with occlusion of the left circumflex artery as the culprit
lesion, ST-segment depression was located exclusively in the
anterior leads in only 5% (4/75). The ST-segment depression in
the anterior leads together with ST-segment depression in the
lateral or inferior leads was present in 13% (10/75) of patients.
Thus, as pointed out by Drs. Almeda and Calvin, to be able to
rapidly identify patients with occlusion of the left circumflex artery
we need better diagnostic techniques than the standard 12-lead
ECG.
Drs. Almeda and Calvin also ask about the outcome in patients
with “normal” (50% stenosis) coronary arteries and an elevated
troponin T level (tnT). In the invasive cohort, 57 patients had
“normal” coronary arteries and an elevated tnT; the median tnT
level among those was 0.23 g/l (10th to 90th percentile, 0.02 to
0.73). Among those 57 patients, 2 patients (3.5%) suffered a
myocardial infarction (MI) and none died during the one-year
follow-up. Thus, this was much lower than the event rates
(approximately 17% MI and 4% death) seen in the patients with
corresponding tnT levels (the two middle quartiles, tnT 0.01 to
0.63 g/l) in the noninvasive cohort. In fact, the event rates among
those with “normal” coronary arteries and an elevated tnT were not
significantly different from those seen in the 101 patients with
“normal” coronary arteries and no tnT elevation (one MI and no
deaths). These data further support the important point that Drs.
Almeda and Calvin make, namely that “troponin elevations are, in
and of itself, not equivalent, and that it is not merely the troponin
elevation, but rather the etiology behind the elevation, that makes
the most difference clinically.”
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Late-Onset Primary LVH:
HCM Versus Cardiac Fabry Variant
In their article that appeared in the August 2001 issue of JACC,
Maron et al. (1) suggest that left ventricular hypertrophy (LVH)
can be a late manifestation of hypertrophic cardiomyopathy
(HCM) due to cardiac myosin-binding protein C (MyBP-C)
mutations. However, the echocardiographically documented LVH
developing in their midlife in patients with MyBP-C mutations
cannot be attributed for certain to that genetic abnormality unless
a histologic demonstration of HCM can be provided by LV
endomyocardial biopsy.
In fact, penetrance of MyBP-C mutations in large series ranges
between 37% and 71% even in patients over 50 years of age (2–4),
and other genetic disorders that give rise to LVH in middle-aged
patients also exist, such as the cardiac variant of Fabry disease (5,6).
This last entity, although X-linked, can occur in both male and
female patients (7), can account for up to 9% of patients with
nonobstructive HCM (8,9) and can be diagnosed simply by
assessment of the alpha-galactosidase A enzymatic activity in the
peripheral blood. If Fabry disease was present even in a proportion
of patients with presumed HCM, those patients could now benefit
from galactose infusion (10) and/or enzyme replacement therapy
(11).
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